NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGV
Post# of 50
(Total Views: 183)
Posted On: 11/13/2023 4:01:36 PM
NetworkNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is reporting on data from a long-term study. According to the announcement, extended long-term, follow-up data from Longeveron’s ELPIS I trial of Lomecel-B(TM) for patients with hypoplastic left heart syndrome (“HLHS”) is being presented as a poster at the annual Scientific Sessions of the American Heart Association (AHA); those sessions are being held this week, Nov. 11-13, 2023, in Philadelphia. The poster for the sessions is titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy.” The poster shows that study data reported 100% of the 10 patients participating in the ELPIS I trial survived and remained heart transplant-free for up to five years of age after receiving Lomecel-B during their stage 2 surgery. Extended follow-up data on all patients enrolled in the study now reflects monitoring for up to five years following treatment with Lomecel-B, with additional follow-up ongoing.
By comparison, historical results from other studies report that children with HLHS experience approximately 20% mortality by five years of age. “Long-term follow-up data from our ELPIS I trial demonstrate the continued survival of the participants, and reinforce potential survival benefit of Lomecel-B for patients with HLHS,” said Longeveron cofounder, chief science officer, and board chair Joshua M. Hare, MD, in the press release. “These data represent an additional up to two years of follow-up data, which point to the potential of Lomecel-B in this indication and provide support for our ongoing ELPIS 2 study, which has exceeded its 50% enrollment threshold. We anticipate completing enrollment in this trial in 2024. There is an unmet need to improve the transplant-free survival for patients with HLHS, and we hope Lomecel-B can significantly improve the treatment landscape for this patient population.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is reporting on data from a long-term study. According to the announcement, extended long-term, follow-up data from Longeveron’s ELPIS I trial of Lomecel-B(TM) for patients with hypoplastic left heart syndrome (“HLHS”) is being presented as a poster at the annual Scientific Sessions of the American Heart Association (AHA); those sessions are being held this week, Nov. 11-13, 2023, in Philadelphia. The poster for the sessions is titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy.” The poster shows that study data reported 100% of the 10 patients participating in the ELPIS I trial survived and remained heart transplant-free for up to five years of age after receiving Lomecel-B during their stage 2 surgery. Extended follow-up data on all patients enrolled in the study now reflects monitoring for up to five years following treatment with Lomecel-B, with additional follow-up ongoing.
By comparison, historical results from other studies report that children with HLHS experience approximately 20% mortality by five years of age. “Long-term follow-up data from our ELPIS I trial demonstrate the continued survival of the participants, and reinforce potential survival benefit of Lomecel-B for patients with HLHS,” said Longeveron cofounder, chief science officer, and board chair Joshua M. Hare, MD, in the press release. “These data represent an additional up to two years of follow-up data, which point to the potential of Lomecel-B in this indication and provide support for our ongoing ELPIS 2 study, which has exceeded its 50% enrollment threshold. We anticipate completing enrollment in this trial in 2024. There is an unmet need to improve the transplant-free survival for patients with HLHS, and we hope Lomecel-B can significantly improve the treatment landscape for this patient population.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Longeveron Inc. (LGVN) Stock Research Links
Scroll down for more posts ▼